All In Biotech

Drug Trial Radar · NCT07559929

A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung Cancer.

A Phase Ib/II Study to Evaluate the Safety and Efficacy of DXC006 for Injection Combined With Immune Checkpoint Inhibitors or Platinum-Based Agents in Patients With Small Cell Lung Cancer.

Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Aug 19, 2026

Primary completion

Jun 1, 2028

Study completion Dec 30, 2030

Sponsor

Sponsor type
Industry
First posted
Apr 30, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase Ib/II, open-label clinical study designed to evaluate the safety, tolerability, preliminary anti-tumor activity, recommended Phase 2 dose (RP2D), pharmacokinetic (PK) characteristics, and immunogenicity of DXC006 in combination with an immune checkpoint inhibitor (ICI) or platinum-based chemotherapy in patients with small cell lung cancer (SCLC).

Conditions

  • Small Cell Lung Cancer

Interventions

  • DXC006Drug

    Participants receive DXC006 intravenously on Day 1 every 3 weeks.

  • ToripalimabDrug

    Participants receive Toripalimab intravenously on Day 1 every 3 weeks.

  • CarboplatinDrug

    Participants receive Carboplatin intravenously on Day 1 every 3 weeks (up to 6 cycles).

  • CisplatinDrug

    Participants receive Cisplatin intravenously on Day 1 every 3 weeks (up to 6 cycles).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS)Time frame: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 year.
  2. 6-month progression-free survival rateTime frame: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 6 months.
  3. Recommended Phase 2 Dose (RP2D)Time frame: Final RP2D confirmation upon completion of the Phase Ib (up to 12 months).
  4. Measurement of objective response rate (ORR) per RECIST 1.1Time frame: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 year.
  5. Measurement of disease control rate (DCR)Time frame: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 year.
  6. Incidence of Adverse Events (AEs)Time frame: After first infusion of study drug, through study completion an average of 2 year.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.